318 related articles for article (PubMed ID: 19304999)
1. Selection, characterization and application of new RNA HIV gp 120 aptamers for facile delivery of Dicer substrate siRNAs into HIV infected cells.
Zhou J; Swiderski P; Li H; Zhang J; Neff CP; Akkina R; Rossi JJ
Nucleic Acids Res; 2009 May; 37(9):3094-109. PubMed ID: 19304999
[TBL] [Abstract][Full Text] [Related]
2. Dual functional RNA nanoparticles containing phi29 motor pRNA and anti-gp120 aptamer for cell-type specific delivery and HIV-1 inhibition.
Zhou J; Shu Y; Guo P; Smith DD; Rossi JJ
Methods; 2011 Jun; 54(2):284-94. PubMed ID: 21256218
[TBL] [Abstract][Full Text] [Related]
3. Development of cell-type specific anti-HIV gp120 aptamers for siRNA delivery.
Zhou J; Li H; Zhang J; Piotr S; Rossi J
J Vis Exp; 2011 Jun; (52):. PubMed ID: 21730942
[TBL] [Abstract][Full Text] [Related]
4. Aptamer-targeted RNAi for HIV-1 therapy.
Zhou J; Rossi JJ
Methods Mol Biol; 2011; 721():355-71. PubMed ID: 21431697
[TBL] [Abstract][Full Text] [Related]
5. Functional in vivo delivery of multiplexed anti-HIV-1 siRNAs via a chemically synthesized aptamer with a sticky bridge.
Zhou J; Neff CP; Swiderski P; Li H; Smith DD; Aboellail T; Remling-Mulder L; Akkina R; Rossi JJ
Mol Ther; 2013 Jan; 21(1):192-200. PubMed ID: 23164935
[TBL] [Abstract][Full Text] [Related]
6. Novel dual inhibitory function aptamer-siRNA delivery system for HIV-1 therapy.
Zhou J; Li H; Li S; Zaia J; Rossi JJ
Mol Ther; 2008 Aug; 16(8):1481-9. PubMed ID: 18461053
[TBL] [Abstract][Full Text] [Related]
7. In Silico Selection of Gp120 ssDNA Aptamer to HIV-1.
Sepehri Zarandi H; Behbahani M; Mohabatkar H
SLAS Discov; 2020 Oct; 25(9):1087-1093. PubMed ID: 32452249
[TBL] [Abstract][Full Text] [Related]
8. Isolation and characterization of 2'-F-RNA aptamers against whole HIV-1 subtype C envelope pseudovirus.
London GM; Mayosi BM; Khati M
Biochem Biophys Res Commun; 2015 Jan; 456(1):428-33. PubMed ID: 25482445
[TBL] [Abstract][Full Text] [Related]
9. Receptor-targeted aptamer-siRNA conjugate-directed transcriptional regulation of HIV-1.
Zhou J; Lazar D; Li H; Xia X; Satheesan S; Charlins P; O'Mealy D; Akkina R; Saayman S; Weinberg MS; Rossi JJ; Morris KV
Theranostics; 2018; 8(6):1575-1590. PubMed ID: 29556342
[TBL] [Abstract][Full Text] [Related]
10. Blocking interaction of viral gp120 and CD4-expressing T cells by single-stranded DNA aptamers.
Zhao N; Pei SN; Parekh P; Salazar E; Zu Y
Int J Biochem Cell Biol; 2014 Jun; 51():10-8. PubMed ID: 24661998
[TBL] [Abstract][Full Text] [Related]
11. Structural characterization of an anti-gp120 RNA aptamer that neutralizes R5 strains of HIV-1.
Dey AK; Griffiths C; Lea SM; James W
RNA; 2005 Jun; 11(6):873-84. PubMed ID: 15923374
[TBL] [Abstract][Full Text] [Related]
12. Potent inhibition of human immunodeficiency virus type 1 replication by template analog reverse transcriptase inhibitors derived by SELEX (systematic evolution of ligands by exponential enrichment).
Joshi P; Prasad VR
J Virol; 2002 Jul; 76(13):6545-57. PubMed ID: 12050367
[TBL] [Abstract][Full Text] [Related]
13. Aptamer-siRNA chimeras for HIV.
Takahashi M; Burnett JC; Rossi JJ
Adv Exp Med Biol; 2015; 848():211-34. PubMed ID: 25757623
[TBL] [Abstract][Full Text] [Related]
14. UCLA1, a synthetic derivative of a gp120 RNA aptamer, inhibits entry of human immunodeficiency virus type 1 subtype C.
Mufhandu HT; Gray ES; Madiga MC; Tumba N; Alexandre KB; Khoza T; Wibmer CK; Moore PL; Morris L; Khati M
J Virol; 2012 May; 86(9):4989-99. PubMed ID: 22379083
[TBL] [Abstract][Full Text] [Related]
15. Incorporation of aptamers in the terminal loop of shRNAs yields an effective and novel combinatorial targeting strategy.
Pang KM; Castanotto D; Li H; Scherer L; Rossi JJ
Nucleic Acids Res; 2018 Jan; 46(1):e6. PubMed ID: 29077949
[TBL] [Abstract][Full Text] [Related]
16. Cell-specific RNA aptamer against human CCR5 specifically targets HIV-1 susceptible cells and inhibits HIV-1 infectivity.
Zhou J; Satheesan S; Li H; Weinberg MS; Morris KV; Burnett JC; Rossi JJ
Chem Biol; 2015 Mar; 22(3):379-90. PubMed ID: 25754473
[TBL] [Abstract][Full Text] [Related]
17. Cell-type-specific aptamer and aptamer-small interfering RNA conjugates for targeted human immunodeficiency virus type 1 therapy.
Zhou J; Rossi J
J Investig Med; 2014 Oct; 62(7):914-9. PubMed ID: 25118114
[TBL] [Abstract][Full Text] [Related]
18. Structural characterization of a 2'F-RNA aptamer that binds a HIV-1 SU glycoprotein, gp120.
Sayer N; Ibrahim J; Turner K; Tahiri-Alaoui A; James W
Biochem Biophys Res Commun; 2002 May; 293(3):924-31. PubMed ID: 12051747
[TBL] [Abstract][Full Text] [Related]
19. An aptamer-siRNA chimera suppresses HIV-1 viral loads and protects from helper CD4(+) T cell decline in humanized mice.
Neff CP; Zhou J; Remling L; Kuruvilla J; Zhang J; Li H; Smith DD; Swiderski P; Rossi JJ; Akkina R
Sci Transl Med; 2011 Jan; 3(66):66ra6. PubMed ID: 21248316
[TBL] [Abstract][Full Text] [Related]
20. Screening Platform toward New Anti-HIV Aptamers Set on Molecular Docking and Fluorescence Quenching Techniques.
Oliviero G; Stornaiuolo M; D'Atri V; Nici F; Yousif AM; D'Errico S; Piccialli G; Mayol L; Novellino E; Marinelli L; Grieco P; Carotenuto A; Noppen S; Liekens S; Balzarini J; Borbone N
Anal Chem; 2016 Feb; 88(4):2327-34. PubMed ID: 26810800
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]